Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
Tetsuo TakeharaNaoya SakamotoShuhei NishiguchiFusao IkedaTomohide TatsumiYoshiyuki UenoHiroshi YatsuhashiYasuhiro TakikawaTatsuo KandaMinoru SakamotoAkihiro TamoriEiji MitaKazuaki ChayamaGulan ZhangShampa De-OertelHadas Dvory-SobolTakuma MatsudaLuisa M StammDiana M BrainardYasuhito TanakaMasayuki KurosakiPublished in: Journal of gastroenterology (2018)
Sofosbuvir-velpatasvir for 12 weeks provides a highly effective and well-tolerated therapy for Japanese patients with HCV and decompensated cirrhosis. Ribavirin did not improve efficacy but increased toxicity.